A Phase 2 Study of Neratinib with or without Fulvestrant in HER2-Positive ER-Positive Metastatic Breast Cancer

T
Tarah Ballinger, MD

Primary Investigator

Overview

The purpose of this research study is to determine how well neratinib, by itself or together with Fulvestrant, works in treating breast cancer that has spread to other parts of the body. We will also be looking at the side effects associated with this combination of drugs.

Description

This is a Phase II study to determine how well neratinib, alone or together with Fulvestrant (FDA approved), works in treating breast cancer that has spread to other parts of the body.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    breast cancer
  • Age: Between 18 Years - 100 Years
  • Gender: Female

Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Females 18 years or older
  • Inoperable locally advanced or metastatic ER+ breast cancer.

For a full list of participation criteria, please visit clinicaltrials.gov.


Additional Information:
Participants will not be paid for their participation.

Updated on 20 Nov 2022. Study ID: 1803730353 (17-318)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center